Molecular Health and Universitätsmedizin Essen [Essen University Hospital] launch collaborative project to improve care for COVID-19 patients
Pioneering project to use clinical data with evidence-based disease model for better diagnosis and therapy in Germany.
On August 1, 2021, the IT biotech company Molecular Health (MH) and Universitätsklinikum Essen kicked off a collaborative project funded by the BMG (Bundesministerium für Gesundheit [German Federal Ministry of Health]) to provide holistic and evidence-based care for COVID-19 patients. Using the MH Corona Explorer, a deeper understanding of the disease will be generated, linking the molecular basis to the clinical course of the disease. The goal is to enable innovative approaches to the diagnosis and treatment of COVID-19 patients and thus improve patient care.